Skip to main content
An official website of the United States government
Email

Publications from the Nanotechnology Characterization Lab

Recent Publications 

Preclinical SC and IV repeat-dose toxicology of a cowpea mosaic virus - A cancer immunotherapy candidate.
Stern ST, Affonso de Oliveira JF, Gatus J, Edmondson E, Neun BW, Dobrovolskaia MA, Steinmetz NF.
Toxicology Reports. 2025; 14: 102022. [PubMed Abstract]

Nanoparticles may influence mast cells gene expression profiles without affecting their degranulation function.
Newton HS, Cedrone E, Grunberger J, Xie S, Zhao Y, Tran B, Toms BS, Xu W, Plant-Hatley A, Liptrott NJ, Dobrovolskaia MA.
Nanomedicine. 2025; 66: 102818. [PubMed Abstract]

Target-specific locked nucleic acid gapmer decreases growth and metastases of pancreatic cancer.
Smith JP, Shivapurkar N, Chen W, Chekuri G, Dabney A, Holmes K, Cao, H, Kularatne R, Stern ST.
Mol Cancer Ther. 2025. [PubMed Abstract]

PLS-alpha-GalCer: a novel targeted glycolipid therapy for solid tumors.
Burks J, Tiwary S, Stevens DM, Skoczen SL, Kularatne RN, Stern ST, Berzofsky JA.
J. Immunother. Cancer. 2025; 13(3): e009539. [PubMed Abstract]

Cellular fate of a plant virus immunotherapy candidate.
Omole AO, Affonso de Oliveira JF, Sutorus L, Karan S, Zhao Z, Neun BW, Cedrone E, Clogston JD, Xu J, Sierk M, Chen Q, Meerzaman D, Dobrovolskaia MA, Steinmetz NF.
Commun Biol. 2024; 7(1): 1382. [PubMed Abstract]

Role of physicochemical properties in silica nanoparticle-mediated immunostimulation.
Grunberger JW, Newton HS, Donohue D, Dobrovolskaia MA, Ghandehari H.
Nanotoxicology. 2024; 18(7): 599-617. [PubMed Abstract]

Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage.
Simms A, Zhao Z, Cedrone E, Dobrovolskaia MA, Steinmetz NF.
Bioeng Transl Med. 2024; 9(6): e10694. [PubMed Abstract]

Immunological properties of silica nanoparticles: a structure-activity relationship study.
Grunberger JW, Dobrovolskaia MA, Ghandehari H.
Nanotoxicology. 2024; 1-23. [PubMed Abstract]

Current state of nanomedicine drug products: An industry perspective.
Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, Torrico Guzmán EA, Walter K, Brown S, Lim Soo P.
J Pharm Sci. 2024. [PubMed Abstract]

In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study.
Cedrone E, Ishaq A, Grabarnik E, Edmondson E, Skoczen S, Neun BW, Freer M, Shuttleworth S, Sviland L, Dickinson A, Dobrovolskaia MA.
Nanomedicine. 2024; 62: 102780. [PubMed Abstract]

Nano-mupirocin as Tumor-Targeted Antibiotic: Physicochemical, Immunotoxicological and Pharmacokinetic Characterization, and Effect on Gut Microbiome.
Cern A, Skoczen SL, Snapp KS, Hod A, Zilbersheid D, Bavli Y, Alon-Maimon T, Bachrach G, Wei X, Berman B, Yassour M, Cedrone E, Neun BW, Dobrovolskaia MA, Clogston JD, Stern ST, Barenholz Y.
J Control Release. 2024; 373: 713-726. [PubMed Abstract]

Characterization of Nanoparticles Intended for Drug Delivery, Third Edition.
Editors: Clogston JD, Crist RM, Dobrovolskaia MA, Stern ST.
Methods in Molecular Biology. 2024; 2789: Humana Press, New York, NY. [Link]

 

For a more comprehensive list of NCL publications, visit our MyNCBI bibliography page.

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Publications from the Nanotechnology Characterization Lab was originally published by the National Cancer Institute.”

Email